TOP FIVE HIGHLIGHTS

1

IVST is up 1000% YTD

IVST is up 1000% TD; from $0.02 on zero revenue to over $0.20 on $4 million revenue.

2

Added $4 Million sales

IVST added $4 million sales run rate YTD through growth model of acquisitions.

3

Pending Acquisition to add $30 Million in Revenue

LOI on Pending Acquisition to add $30 Million in revenue. CEO calls it transformational” and the first of several planned.

4

11.8M Shares in the Float

11.8M shares in the Float, unchanged for over two years.

5

No Convertible Debts, Warrants, or Options

IVST has no convertible debts, warrants, or options.

IVST announced that it expects to close the acquisition of a $30 million revenue generating construction materials supply company in the first half of September 2018. Announcement Pending!

In addition to an expected 2018 annual revenue run rate of $30 Million (+) in revenue, IVST also launched a biotech division which owns a stake in the brain cancer vaccine, StemVax Glioblast (SVX-GB), including the patent number #US9764014B2 with it's investment in StemVax Therapeutics which was recently featured in the LA Business Journal in August.

IVST is a rare high growth opportunity, with rapidly growing revenue, valuable intellectual property, VERY few shares available, and ZERO debt.
Management has disclosed plans to list IVST on the Nasdaq or NYSE as soon as possible, based on it's current trajectory which includes stock price increases of 1000% Year To Date.
To visit the IVST website, click here.